Compare FFWM & IRWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FFWM | IRWD |
|---|---|---|
| Founded | 1990 | 1998 |
| Country | United States | United States |
| Employees | 485 | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 473.3M | 526.7M |
| IPO Year | 2014 | 2009 |
| Metric | FFWM | IRWD |
|---|---|---|
| Price | $5.91 | $3.45 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 3 | 5 |
| Target Price | ★ $6.17 | $4.94 |
| AVG Volume (30 Days) | 903.8K | ★ 2.3M |
| Earning Date | 04-29-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 1400.00 |
| EPS | N/A | ★ 0.15 |
| Revenue | $34,373,000.00 | ★ $298,276,000.00 |
| Revenue This Year | $56.34 | $57.95 |
| Revenue Next Year | $10.68 | $4.39 |
| P/E Ratio | ★ N/A | $23.53 |
| Revenue Growth | N/A | ★ 8.88 |
| 52 Week Low | $4.42 | $0.55 |
| 52 Week High | $6.72 | $5.78 |
| Indicator | FFWM | IRWD |
|---|---|---|
| Relative Strength Index (RSI) | 51.22 | 47.85 |
| Support Level | $5.44 | $3.07 |
| Resistance Level | $5.97 | $3.53 |
| Average True Range (ATR) | 0.19 | 0.22 |
| MACD | 0.03 | 0.07 |
| Stochastic Oscillator | 80.63 | 44.26 |
First Foundation Inc is a financial services company. It is engaged in providing investment management and financial planning services for high-net-worth individuals, retirement plans, charitable institutions, and private foundations. The company focuses on segments namely Banking and Wealth Management. It also offers loans to individuals and entities that own and operate multifamily residential and commercial real estate properties as well as business banking products and services to small to moderate-sized businesses, professional firms, and consumer banking products and services to individuals.
Ironwood Pharmaceuticals Inc is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal, or GI, and rare diseases. It is focused on the development and commercialization of inventive product opportunities in areas of unmet need, leveraging its demonstrated expertise and capabilities in GI and rare diseases. LINZESS is its commercial product. LINZESS is also available for the treatment of adults with IBS-C or CIC in Mexico, adults with IBS-C or chronic constipation in Japan, and adults with IBS-C in China. Linaclotide is available under the trademarked name CONSTELLA for the treatment of adults with IBS-C or CIC and pediatric patients ages 6-17 years old with FC in Canada, and to adults with IBS-C in certain European countries.